openPR Logo
Press release

Lumateperone (Caplyta) by Intra-Cellular Therapies Inc. expected to drive market size of Major Depressive Disorder

02-21-2024 07:18 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Lumateperone (Caplyta) by Intra-Cellular Therapies Inc.

[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on Lumateperone (Intra-Cellular Therapies Inc.) providing insights into the drug market landscape and market forecast of Lumateperone (Caplyta) upto 2032. The report, titled "XXXXX" is now available for review and analysis.
Are you interested in finding out the projected market size of Lumateperone in 2032? Lumateperone Market Forecast https://www.delveinsight.com/report-store/lumateperone-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
The Lumateperone Market Report offers projected sales forecasts for Lumateperone for indications until 2032, categorized across the 7MM i.e. United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report also provides extensive coverage and a competitive landscape analysis of competitors and marketed products indication. It also covers analyst views along with market drivers and barriers.
Intra-Cellular Therapies Inc.'s Lumateperone is serving as a beacon of hope for the patients suffering from the Major Depressive Disorder.
What is a Lumateperone (Caplyta) Prescribed for?
Lumateperone is prescribed for the management of schizophrenia. Additionally, it is utilized either independently or in combination with other medications like lithium or valproate to address depressive episodes in individuals with bipolar I or II disorder (bipolar depression). It is important to note that this medication is not intended for addressing behavioral issues in elderly patients with dementia.

The report extensively covers the details and developments related to Lumateperone, capturing important highlights on developmental pipeline, regulatory status and special designations of Lumateperone, route of administration, safety and efficacy details.

Lumateperone (Caplyta) Market Assessment
This report provides a detailed market assessment of Lumateperone for Major Depressive Disorder in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2028 to 2032.

Lumateperone (Caplyta) Clinical Assessment
The report provides the clinical trials information of Lumateperone for Major Depressive Disorder covering trial interventions, trial conditions, trial status, start and completion dates. Report also includes important insights on regulatory milestones and other developmental activities related.
Do you know your drug's competitive positioning against Lumateperone? Lumateperone Drugs Insights https://www.delveinsight.com/sample-request/lumateperone-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Lumateperone Competitive Landscape
The report offers insights into the key players and companies actively engaged in the development of the specified indication. It provides valuable information regarding the competitive positioning of the Lumateperone.

Lumateperone Market Size in the US
A dedicated section of the report focuses on the expected market size of Lumateperone for the United States. DelveInsight's analysis includes market trends, growth projections, and key factors influencing the market dynamics, offering a comprehensive perspective for stakeholders.

Key Highlights of Lumateperone:

• The report contains forecasted sales of Lumateperone for indication till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Major Depressive Disorder.
• The report also features the qualitative and quantitative analysis with analysts as well as KOL views for Lumateperone in Major Depressive Disorder.
Stay ahead in competition by leveraging insights on Lumateperone market Report: Download Lumateperone Market Report
https://www.delveinsight.com/sample-request/lumateperone-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Why you should buy Lumateperone Market Report:
• The report provides future market assessments for Lumateperone for Major Depressive Disorder in the 7 Major Markets, Advance qualitative analysis like SWOT, expert analysts' views, detailed overview of market competitors, and short analysis of other emerging therapies in Ulcerative Colitis.
• Leading Lumateperone for Major Depressive Disorder forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Lumateperone
• Discover the competitive landscape of Lumateperone through 7MM
• Get a Thorough Analysis of the Lumateperone Development pipeline, Safety & Efficacy of the Lumateperone, and ROA
• Thorough Lumateperone market forecast will help understand how drug is competing with other emerging Lumateperone
• Get analysis of the Lumateperone clinical trial advancements and the detailed clinical assessment, regulatory and commercial assessment
• Drug Market forecasts are calculated after taking into consideration KOL viewpoints

Related Reports By DelveInsight:

Major Depressive Disorder Pipeline https://www.delveinsight.com/report-store/major-depressive-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's, "Major Depressive Disorder Pipeline Insight, 2024" report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Major Depressive Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. The Key Major Depressive Disorder companies developing therapies include - GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals, and others.
It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Top Services Offered By DelveInsight:
Elevate healthcare strategies with Delveinsight Healthcare Consulting. Unlock insights, navigate challenges, and drive success in the dynamic healthcare landscape. https://www.delveinsight.com/consulting

Recent Reports Offered By DelveInsight:

Ventricular Assist Devices Market https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market
Ventricular Assist Devices Market By Product Type (Left Ventricular Assist Devices, Right Ventricular Assist Devices, And Biventricular Assist Devices), By Application Type (Bridge-To-Transplant [Btt], Destination Therapy, And Others), By Design Type (Transcutaneous Ventricular Assist Devcies And Implantable Ventricular Assist Devices), By Type Of Flow (Pulsatile Flow And Continous Flow), By End User (Hospital And Clinics, Ambulatory Surgical Centers, And Others), by geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing prevalence of heart failure and cardiovascular diseases due to obesity, age, & unhealthy lifestyles and rising demand for organ transplants due to increasing prevalence of chronic ailments such as hypertension, diabetes, and others

B-cell Non-hodgkin Lymphoma Market https://www.delveinsight.com/report-store/b-cell-non-hodgkin-lymphoma-market
DelveInsight's "B-Cell Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the B-Cell Non-Hodgkin Lymphoma, historical and forecasted epidemiology as well as the B-Cell Non-Hodgkin Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Systemic Sclerosis Market
https://www.delveinsight.com/report-store/systemic-sclerosis-market
DelveInsight's "Systemic Sclerosis Market Insights, Epidemiology, and Market Forecast - 2032" comprehensively analyzes Systemic Sclerosis. The report includes a detailed examination of the historical and projected epidemiology data that includes diagnosed prevalent cases of Systemic Sclerosis segmented by gender-specific, age-specific, and type-specific cases.

Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
"DelveInsight's 'Resorbable Vascular Scaffolds Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vascular Stents Market
https://www.delveinsight.com/report-store/vascular-stents-market
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2028 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Bladder Scanners Market
https://www.delveinsight.com/report-store/bladder-scanners-market
"DelveInsight's 'Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vein Illumination Devices Market
https://www.delveinsight.com/report-store/vein-illumination-devices-market
"DelveInsight's 'Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to launch of advanced devices and increasing prevalence of respiratory diseases such as COPD.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lumateperone (Caplyta) by Intra-Cellular Therapies Inc. expected to drive market size of Major Depressive Disorder here

News-ID: 3394137 • Views:

More Releases from DelveInsight Business Research

Hepatorenal Syndrome Pipeline Assessment 2024: Clinical Trials, FDA Approvals, Therapies, ROA, MOA and Key Companies involved by DelveInsight
Hepatorenal Syndrome Pipeline Assessment 2024: Clinical Trials, FDA Approvals, T …
(Albany, United States) As per DelveInsight's assessment, globally, the Hepatorenal Syndrome Pipeline constitutes 3+ key companies continuously working towards developing 3+ Hepatorenal Syndrome Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight. In the Hepatorenal Syndrome Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Hepatorenal Syndrome NDA approvals (if
Parkinson's Disease Psychosis Pipeline Assessment 2024: Clinical Trials, FDA Approvals, Therapies, ROA, MOA and Key Companies involved by DelveInsight
Parkinson's Disease Psychosis Pipeline Assessment 2024: Clinical Trials, FDA App …
(Albany, United States) As per DelveInsight's assessment, globally, the Parkinson's disease Psychosis Pipeline constitutes 5+ key companies continuously working towards developing 5+ Parkinson's Disease Psychosis Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight. In the Parkinson's Disease Psychosis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any),
Oral Mucositis Pipeline Analysis, 2024: Clinical Trials, FDA Approvals, Therapies, Mechanism of Action, Route of Administration by DelveInsight
Oral Mucositis Pipeline Analysis, 2024: Clinical Trials, FDA Approvals, Therapie …
(Albany, United States) As per DelveInsight's assessment, globally, the Oral Mucositis Pipeline constitutes 10+ key companies continuously working towards developing 10+ Oral Mucositis Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight. In the Oral Mucositis Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Oral Mucositis NDA approvals (if any), and
Necrotizing Enterocolitis Pipeline Analysis, 2024: Clinical Trials, FDA Approvals, Therapies, ROA, MOA and Key Companies by DelveInsight | Abbott, Astellas Pharma, Bayer, Becton, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly
Necrotizing Enterocolitis Pipeline Analysis, 2024: Clinical Trials, FDA Approval …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Necrotizing Enterocolitis pipeline constitutes 4+ key companies continuously working towards developing 4+ Necrotizing Enterocolitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Necrotizing Enterocolitis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Necrotizing Enterocolitis Market. The Necrotizing Enterocolitis Pipeline report embraces

All 5 Releases


More Releases for Lumateperone

The Bipolar Depression Market is growing at a Significant CAGR Driven by the Pot …
DelveInsight's Bipolar Depression market report provides thorough comprehension of Bipolar Depression, historical and forecasted epidemiology, and Bipolar Depression market trends in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan). As per DelveInsight analysis, the Bipolar Depression market will experience a significant impact in the coming years owing to the increase in awareness and technology, advancement towards precision medicine, expected launch of emerging drugs, entry
Bipolar Disorder Therapeutics Drugs Market to Eyewitness Huge Growth by 2027 wit …
Different investors, stakeholders and businesses and governments get huge help from this Bipolar Disorder Therapeutics Drugs market study report to understand the difficult areas of marketing concept, technological progress, critical concerns and regulatory landscape for accomplishing long-term success in the business. It goes on covering basic characteristics of the market such as driving factors, restraining factors, current challenges, upcoming opportunities and prospects. Extrinsic elements such as threats and obstacles and
Depression Therapeutics Market To Surpass US$ 14,814.9 Million Threshold By 2027 …
The high prevalence and incidence rate of mental disorders such as anxiety, major depressive disorder, and associated co-morbidities are playing a significant role in the overall development of the depression therapeutics market. According to the World Health Organization, depression is a common mental disorder and one of the main causes of disability worldwide. Globally, an estimated 264 million people are affected by depression. More women are affected than men. Low
Bipolar Depression Pipeline Market 2020 Insight, Key Players are Sunovion, Sumit …
Bipolar Depression Pipeline Market Insight, 2020, report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Bipolar Depression pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered - Global coverage Key Players - Sunovion - Sumitomo Pharmaceutical - H. Lundbeck A/S -
Lumateperone– Drug Launch Insight, 2018
Lumateperone by Intra-Cellular Therapies Inc., has multiple mechanisms, such as that of a potent serotonin 5-HT2A receptor antagonist; a dopamine receptor phosphoprotein modulator (DPPM), acting as a presynaptic partial agonist and postsynaptic antagonist at dopamine D2 receptors, a dopamine D1 receptor-dependent indirect modulator of glutamate (both NDMA and AMPA), and a serotonin reuptake inhibitor. Download the sample report at: https://www.pharmaproff.com/report/lumateperone It is currently under review by the United States Food and
Schizophrenia: Disease Insights & Market Forecasts to 2024 by Pharmascroll
“Schizophrenia: Disease Insights and Market Forecasts to 2024” report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Schizophrenia disease in the US, EU5 (Germany, France, Italy, Spain, UK), and Japan and the historical & forecasted market size, for Schizophrenia, drug wise in $ sales and patient numbers at global level and in the US, EU5 (Germany, France, Italy, Spain, UK), Australia and Canada till 2024. Geographies covered: US Germany France Italy Spain UK Japan Australia Canada Drugs